Everest Medicines launches personalized mRNA cancer vaccine trial

Everest Medicines has commenced an investigator-initiated clinical trial (IIT) of its personalised mRNA cancer vaccine, EVM16.

The trial, named EVM16CX01, is being conducted at the Peking University Cancer Hospital and Fudan University’s Cancer Hospital in China.